BTIG initiated coverage of Annexon (NASDAQ:ANNX) with a “buy” rating and $15 price target. The stock closed at $6.02 on Sept. 8. Annexon, Inc. is a development-stage biotech company focused on mediating the role of...
Cantor Fitzgerald initiated coverage of Annexon (NASDAQ:ANNX) with an “overweight” rating and $40 price target. The stock closed at $21.12 on Sept. 22. Annexon is a platform-enabled therapeutics company focused on...
Annexon (NASDAQ:ANNX) launched a Phase 2 trial evaluating ANX005 for the treatment of Huntington’s disease. ANX005 is a monoclonal antibody designed to inhibit the complement protein, C1q. “Huntington’s disease is a...